Veracyte (VCYT) Enterprise Value (2016 - 2025)
Veracyte (VCYT) has disclosed Enterprise Value for 14 consecutive years, with -$362.6 million as the latest value for Q4 2025.
- Quarterly Enterprise Value fell 51.65% to -$362.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$362.6 million through Dec 2025, down 51.65% year-over-year, with the annual reading at -$362.6 million for FY2025, 51.65% down from the prior year.
- Enterprise Value hit -$362.6 million in Q4 2025 for Veracyte, down from -$315.6 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$153.4 million in Q2 2022 to a low of -$362.6 million in Q4 2025.
- Historically, Enterprise Value has averaged -$223.0 million across 5 years, with a median of -$205.8 million in 2023.
- Biggest five-year swings in Enterprise Value: crashed 122.14% in 2021 and later surged 53.15% in 2022.
- Year by year, Enterprise Value stood at -$173.2 million in 2021, then increased by 10.94% to -$154.2 million in 2022, then tumbled by 40.33% to -$216.5 million in 2023, then decreased by 10.46% to -$239.1 million in 2024, then crashed by 51.65% to -$362.6 million in 2025.
- Business Quant data shows Enterprise Value for VCYT at -$362.6 million in Q4 2025, -$315.6 million in Q3 2025, and -$219.5 million in Q2 2025.